Discover OncoCyte's Q4 2024 progress with its cutting-edge kidney transplant test. Insights on FDA ambitions, market strategies & financial runway.

The conservative Pelican Institute has released a report outlining four ways to reduce criminal recidivism and thus make ...

Specific changes are needed to lower the barriers to entry for using the hospital and insurer price transparency data, ...

Shorter trial authorisation timelines for ATMP trials in the US are an advantage for biotechs, say experts. Although the ...

The company's objective was to assess the essential documentation for submission, determine the necessity of conducting ...

ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

The country is also advancing the integration of TCM into modern healthcare by optimizing its clinical use and expanding ...

Towards Healthcare continued; “The global AI in diagnostics market was estimated at US$ 1.12 billion in 2023 and is projected to grow to US$ 12.65 billion by 2034, rising at a compound annual growth ...

Today, there is now reliable evidence that digitally enabled trials provide value and can solve some of the most chronic ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...